

# Raffaele De Caterina

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7964955/raffaele-de-caterina-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287  
papers

29,454  
citations

63  
h-index

170  
g-index

335  
ext. papers

34,294  
ext. citations

6.1  
avg, IF

6.76  
L-index

#	Paper	IF	Citations
287	Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model.. <i>Journal of Cellular and Molecular Medicine</i> , <b>2022</b> ,	5.6	1
286	Rivaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial.. <i>International Journal of Cardiology</i> , <b>2022</b> ,	3.2	2
285	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.. <i>Vascular Pharmacology</i> , <b>2022</b> , 106994	5.9	
284	Response to "non-vitamin K antagonist oral anticoagulants (NOACs) in preventing thromboembolism in atrial fibrillation patients with moderate to severe mitral stenosis: Results from a pilot trial" .. <i>International Journal of Cardiology</i> , <b>2022</b> ,	3.2	
283	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-NCS.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024292	6	0
282	Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and dysfunction: A potential rescue strategy. <i>Vascular Pharmacology</i> , <b>2021</b> , 142, 106949	5.9	1
281	ST-segment/heart rate hysteresis improves the exercise testing accuracy for coronary artery detection in asymptomatic patients with severe aortic stenosis. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 323-325	1.9	2
280	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , <b>2021</b> , 144, 1323-1343	16.7	9
279	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	1
278	A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19). <i>European Heart Journal - Case Reports</i> , <b>2021</b> , 5, ytaa339	0.9	5
277	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , <b>2021</b> , 8,	3	1
276	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , <b>2021</b> , 84, 485-490	2.8	1
275	Extent and progression of atherosclerosis in carotid and subclavian arteries: the Carotid Artery Subclavian Artery study. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 652-656	1.9	
274	Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. <i>Patient</i> , <b>2021</b> , 14, 661-672	3.7	0
273	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , <b>2021</b> , 42, 2610-2612	9.5	13
272	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13562	4.6	2
271	Excessive Orthostatic Changes in Blood Pressure Are Associated With Incident Heart Failure in Older Men: A Prospective Analysis From the BRHS. <i>Hypertension</i> , <b>2021</b> , 77, 1481-1489	8.5	

270	Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
269	Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 5381-5390	5.6	2
268	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 2148-2160	8.9	8
267	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
266	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e006852	5.8	3
265	A highly-detailed anatomical study of normal pericardial structures as revealed by in-vivo computed tomography and magnetic resonance images and ex-vivo novel 3D reconstructions from Visible Human Server. <i>Imaging</i> , <b>2021</b> , 13, 1-12	0.3	
264	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f30-f39	6.4	10
263	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , <b>2021</b> , 136, 106809	5.9	2
262	PCSK9 and atherosclerosis: Looking beyond LDL regulation. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13459	4.6	13
261	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 591-599	3.7	3
260	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13400	4.6	2
259	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , <b>2021</b> , 76, 431-439	0.9	
258	Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?. <i>European Heart Journal</i> , <b>2021</b> , 42, 1444-1445	9.5	1
257	Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> ,	1.5	11
256	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
255	Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence. <i>European Heart Journal - Case Reports</i> , <b>2021</b> , 5, ytaa577	0.9	
254	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , <b>2021</b> , 42, 4389-4400	9.5	10
253	Interpreting myocardial infarction analyses in ISCHEMIA: separating facts from fallacy. <i>European Heart Journal</i> , <b>2021</b> , 42, 2986-2989	9.5	0

252	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	1
251	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. <i>Vascular Pharmacology</i> , <b>2021</b> , 139, 106888	5.9	0
250	Coronary Artery Anomalies. <i>Circulation</i> , <b>2021</b> , 144, 983-996	16.7	7
249	Eighty years of oral anticoagulation: Learning from history. <i>Vascular Pharmacology</i> , <b>2021</b> , 141, 106918	5.9	1
248	Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	2
247	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1745-1757	4.0	7.0
246	Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. <i>Vascular Pharmacology</i> , <b>2020</b> , 135, 106807	5.9	3
245	Imaging of the vulnerable carotid plaque: Role of imaging techniques and a research agenda. <i>Neurology</i> , <b>2020</b> , 94, 922-932	6.5	12
244	Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy. <i>Hypertension</i> , <b>2020</b> , 76, 312-313	8.5	8
243	Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2020</b> , 318, 82-85	3.2	3
242	Comparison of Dabigatran Plus a P2Y Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 1302-1312	2.4	1
241	Where are clots in atrial fibrillation? Did we have the wrong assumptions over the last decades?. <i>Europace</i> , <b>2020</b> , 22, 845-846	3.9	2
240	Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	12
239	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , <b>2020</b> , 318, 67-73	3.2	4
238	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , <b>2020</b> , 395, 865	4.0	2
237	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13221	4.6	0
236	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1145-1155	15.1	19
235	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	9

234	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1374-1380	6.1	2
233	From short-term blood pressure variability to atherosclerosis: Relative roles of vascular stiffness and endothelial dysfunction. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 1218-1227	2.3	8
232	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
231	Should We Continue Assessing Glomerular Filtration Rate with the Cockcroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
230	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1093-1104	3.7	2
229	Prevention of contrast-induced nephropathy with urine alkalization: the TEATE study design. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 65-72	1.9	1
228	Co-expression of glycosylated aquaporin-1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis-prone mice. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 2857-2865	5.6	4
227	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes - A call to action. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 5-7	3.2	0
226	Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism. <i>Vascular Pharmacology</i> , <b>2020</b> , 130, 106678	5.9	9
225	Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. <i>Anatolian Journal of Cardiology</i> , <b>2020</b> , 23, 70-78	0.8	4
224	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 121-129	1.9	2
223	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> ,	6.4	2
222	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. <i>Vascular Pharmacology</i> , <b>2020</b> , 125-126, 106648	5.9	3
221	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 199-206	7	4
220	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 857-864	1.6	3
219	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 751-758	3.758	4
218	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , <b>2020</b> , 141, 10-20	16.7	11
217	Challenges in ischaemic heart disease: not sleeping enough, not brushing your teeth, and skipping breakfast-three ways of increasing your risk of myocardial infarction?. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, L57-L60	1.5	1

216	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , <b>2020</b> , 113, 642-651	2.7	3
215	The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. <i>European Heart Journal</i> , <b>2020</b> , 41, 3113-3116	9.5	2
214	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant Or, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
213	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2015943	10.4	2
212	Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 12331-12340	5.6	9
211	Mortality Prediction of the CHADS-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
210	The Nutrigenetics of Cardiovascular Disease <b>2020</b> , 355-360		0
209	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 95-99.e6	2.4	9
208	Why include the humanities in medical studies?. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 523-524	3.7	
207	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 1147-1154	3.3	8
206	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1773-1784	7	11
205	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	28
204	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 749-757.e5	2.4	34
203	Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2019</b> , 131, 171-186	5.8	11
202	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1013-1025	9.9	25
201	Antioxidant and Anti-Inflammatory Properties of Oil in Human Pre-Adipocytes. <i>Antioxidants</i> , <b>2019</b> , 8,	7.1	49
200	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , <b>2019</b> , 9, e022478	3	29
199	Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?. <i>Vascular Pharmacology</i> , <b>2019</b> , 116, 45-50	5.9	13

198	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2019</b> , 35, e3145	7.5	4
197	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , <b>2019</b> , 40, 237-269	9.5	851
196	CHADSVASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1987-1997	3.9	12
195	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , <b>2019</b> , 19, 165	2.3	16
194	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1286-1292	3	20
193	Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	25
192	Is there an 'atherosclerotic continuum' from angina with unobstructed coronary arteries to MINOCA? Reply. <i>European Heart Journal</i> , <b>2019</b> , 40, 1988	9.5	1
191	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , <b>2019</b> , 21, 1633-1638	3.9	9
190	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 144	8.7	21
189	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , <b>2019</b> , 286, 198-207	3.2	13
188	The Extra-Virgin Olive Oil Polyphenols Oleocanthal and Oleacein Counteract Inflammation-Related Gene and miRNA Expression in Adipocytes by Attenuating NF- $\kappa$ B Activation. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	41
187	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 14-38	7	19
186	Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the Edoxaban versus warfarin in subjects Undergoing cardioversion Of Atrial Fibrillation (ENSURE-AF) trial. <i>American Heart Journal</i> , <b>2019</b> , 209, 131-135	4.9	1
185	Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , <b>2019</b> , 20, 97-104	1.9	13
184	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , <b>2019</b> , 283, 78-83	3.2	16
183	The first 3500 years of aspirin history from its roots - A concise summary. <i>Vascular Pharmacology</i> , <b>2019</b> , 113, 1-8	5.9	65
182	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , <b>2019</b> , 16, 113-130	14.8	37
181	Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , <b>2018</b> , 39, 2135-2146	9.5	54

180	Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. <i>Vascular Pharmacology</i> , <b>2018</b> ,	5.9	25
179	Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 35-52	9.9	125
178	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , <b>2018</b> , 265, 141-147	3.2	26
177	Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography. <i>Radiologia Medica</i> , <b>2018</b> , 123, 643-654	6.5	15
176	Innate and adaptive immunity in atherosclerosis. <i>Vascular Pharmacology</i> , <b>2018</b> , 107, 67-67	5.9	32
175	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19 Suppl 1, e40-e45	1.9	1
174	Coronary computed tomography angiography, ECG stress test and nuclear imaging as sources of false-positive results in the detection of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19 Suppl 1, e133-e138	1.9	2
173	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , <b>2018</b> , 111, 74-84	2.7	14
172	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , <b>2018</b> , 267, 68-73	3.2	18
171	Cell based mechanosensing in vascular patho-biology: More than a simple go-with the flow. <i>Vascular Pharmacology</i> , <b>2018</b> , 111, 7-14	5.9	12
170	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , <b>2018</b> , 265, 118-124	3.2	13
169	Is Complete Revascularisation Mandated for all Patients with Multivessel Coronary Artery Disease?. <i>Interventional Cardiology Review</i> , <b>2018</b> , 13, 45-50	4.2	7
168	Three-Dimensional Echographic Evaluation of Carotid Artery Disease. <i>Journal of Cardiovascular Echography</i> , <b>2018</b> , 28, 218-227	0.6	11
167	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation [ENSURE-AF] Study). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 193-198	3	5
166	Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?. <i>Circulation</i> , <b>2018</b> , 138, 1356-1365	16.7	22
165	Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1745-1753	3	18
164	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 160-166	3.2	15
163	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 409-419	15.1	46



162	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Española De Cardiología</i> , <b>2017</b> , 70, 50.e1-50.e84	1.5	6
161	Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. <i>Vascular Pharmacology</i> , <b>2017</b> , 90, 1-7	5.9	64
160	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , <b>2017</b> , 232, 98-104	3.2	13
159	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , <b>2017</b> , 34, 620-637	4.1	6
158	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , <b>2017</b> , 103, 1024-1030	5.1	66
157	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , <b>2017</b> , 135, 1273-1275	16.7	94
156	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , <b>2017</b> , 59, e277-e281	0.3	2
155	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 565-572	6.1	40
154	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2017</b> , 24, 331-339	2.9	6
153	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1089-1094	12.3	3
152	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1363-1371	15.1	84
151	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172800	3.7	9
150	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	93
149	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. <i>International Journal of Cardiology</i> , <b>2017</b> , 244, 112-118	3.2	6
148	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 457-461	2.4	16
147	Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1230-1239	7	265
146	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , <b>2017</b> , 38, 877-887	9.5	41
145	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , <b>2016</b> , 18, 6-11	3.9	27

144	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromes--The COPACS Study. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 105-14	2.4	4
143	Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, 3-12	2.7	43
142	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , <b>2016</b> , 37, 2893-2962	9.5	4465
141	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , <b>2016</b> , 18, 1609-1678	3.9	1293
140	Heart failure due to right ventricular apical pacing: the importance of flow patterns. <i>Europace</i> , <b>2016</b> , 18, 1679-1688	3.9	19
139	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 1117-1123.e2	2.4	12
138	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia</i> , <b>2016</b> , 35, 319-21	1	
137	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , <b>2016</b> , 30, 201-14	3.9	15
136	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. <i>Atherosclerosis</i> , <b>2016</b> , 248, 216-8	3.1	14
135	Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) $\alpha$ / $\gamma$ agonist aleglitazar in attenuating TNF $\alpha$ -mediated inflammation and insulin resistance in human adipocytes. <i>Pharmacological Research</i> , <b>2016</b> , 107, 125-136	10.2	35
134	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , <b>2016</b> , 81, 1-14	5.9	6
133	High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 18	8.7	53
132	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , <b>2016</b> , 175, 175-83	4.9	10
131	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 165-71	3	21
130	Extra virgin olive oil rich in polyphenols modulates VEGF-induced angiogenic responses by preventing NADPH oxidase activity and expression. <i>Journal of Nutritional Biochemistry</i> , <b>2016</b> , 28, 19-29	6.3	41
129	C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. <i>European Heart Journal</i> , <b>2016</b> , 37, 1762-71	9.5	55
128	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 685-711	7	21
127	Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 1012-1021	7	30

126	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. <i>Cardiovascular Drugs and Therapy</i> , <b>2016</b> , 30, 465-472	3.9	5
125	ST segment/heart rate hysteresis improves the diagnostic accuracy of ECG stress test for coronary artery disease in patients with left ventricular hypertrophy. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1632-9	3.9	4
124	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. <i>European Heart Journal Supplements</i> , <b>2016</b> , 18, I1-I6	1.5	1
123	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , <b>2016</b> , 7, 1541-50	1.2	1
122	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , <b>2016</b> , 35, 319-321	0	
121	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2016</b> , 50, e1-e88	3	589
120	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 345-6	3.3	46
119	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 115-7	3.7	1
118	Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. <i>International Journal of Cardiology</i> , <b>2015</b> , 197, 241-7	3.2	23
117	Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. <i>Cardiovascular Drugs and Therapy</i> , <b>2015</b> , 29, 469-79	3.9	17
116	Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. <i>Cardiovascular Research</i> , <b>2015</b> , 108, 39-49	9.9	45
115	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , <b>2015</b> , 36, 3238-49	9.5	129
114	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 1007-14.e2	2.4	29
113	Circulating endothelial progenitor cells: Do they live up to their name?. <i>Vascular Pharmacology</i> , <b>2015</b> , 67-69, 2-5	5.9	43
112	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. <i>Thrombosis Research</i> , <b>2015</b> , 136, 308-14	8.2	7
111	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 798-807	1.2	20
110	Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 848-860	15.1	229
109	Role and importance of ultrasound lung comets in acute cardiac care. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 103-12	4.3	13

108	Bivalirudin for acute coronary syndromes: premises, promises and doubts. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 698-707	7	13
107	Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128218	3.7	38
106	Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. <i>European Heart Journal</i> , <b>2015</b> , 36, 1609-17	9.5	168
105	Transcriptome-based identification of new anti-inflammatory and vasodilating properties of the n-3 fatty acid docosahexaenoic acid in vascular endothelial cell under proinflammatory conditions [corrected]. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129652	3.7	7
104	Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis. <i>Current Drug Targets</i> , <b>2015</b> , 16, 361-5	3	10
103	Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers. <i>Archives Italiennes De Biologie</i> , <b>2015</b> , 153, 25-36	1.1	3
102	Transplantation of mesenchymal cells improves peripheral limb ischemia in diabetic rats. <i>Molecular Biotechnology</i> , <b>2014</b> , 56, 438-48	3	14
101	Proton pump inhibitors and clopidogrel: an association to avoid?. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 11-22	3.7	10
100	Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2141-2147	15.1	260
99	The dynamics of the coronary collateral circulation. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 191-7	14.8	61
98	Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 453-63	5	73
97	Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC $\beta$ and PKC $\delta$ inhibition. <i>Atherosclerosis</i> , <b>2014</b> , 232, 17-24	3.1	88
96	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , <b>2014</b> , 130, 1847-58	16.7	188
95	High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2014</b> , 1842, 2266-75	6.9	25
94	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , <b>2014</b> , 100, 1625-35	5.1	20
93	Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 319-27	15.1	123
92	Co-activation of nuclear factor- $\kappa$ B and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 19585-98	5.4	19
91	The WOEST study: Critical considerations and applicability. <i>Cor Et Vasa</i> , <b>2014</b> , 56, e254-e258	0.3	8

90	Involvement of the TP receptor in TNF- $\beta$ -induced endothelial tissue factor expression. <i>Vascular Pharmacology</i> , <b>2014</b> , 62, 49-56	5.9	20
89	Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 833-41	7	77
88	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events--European Registry in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , <b>2014</b> , 16, 6-14	3.9	283
87	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1864-72	9.5	237
86	Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. <i>Vascular Pharmacology</i> , <b>2014</b> , 60, 49-51	5.9	3
85	Reprint of Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. <i>Vascular Pharmacology</i> , <b>2014</b> , 62, 120-122	5.9	1
84	Ranolazine in the prevention of anthracycline cardiotoxicity. <i>Pharmacological Research</i> , <b>2014</b> , 79, 88-102	10.2	20
83	Long-term engraftment and angiogenic properties of lentivirally transduced adipose tissue-derived stromal cells. <i>Molecular Biotechnology</i> , <b>2013</b> , 54, 13-24	3	6
82	Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications. <i>Vascular Pharmacology</i> , <b>2013</b> , 59, 127-30	5.9	7
81	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?. <i>Vascular Pharmacology</i> , <b>2013</b> , 59, 53-62	5.9	20
80	General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 569-79	7	134
79	Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational studies. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 687-95	5	61
78	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , <b>2013</b> , 127, 2166-76	16.7	164
77	Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells. <i>Molecular Biotechnology</i> , <b>2013</b> , 55, 169-78	3	14
76	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 769-86	7	31
75	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1087-107	7	278
74	Relevance of new drug discovery to reduce NF- $\kappa$ B activation in cardiovascular disease. <i>Vascular Pharmacology</i> , <b>2012</b> , 57, 41-7	5.9	34
73	Nitrates and other nitric oxide donors in cardiology: current positioning and perspectives. <i>Cardiovascular Drugs and Therapy</i> , <b>2012</b> , 26, 55-69	3.9	14

72	Isolated troponin increase after percutaneous coronary interventions: does it have prognostic relevance?. <i>Atherosclerosis</i> , <b>2012</b> , 221, 297-302	3.1	20
71	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2012</b> , 65, 309-313	0.7	2
70	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , <b>2012</b> , 14, 1385-413	3.9	1019
69	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. <i>Archives of Biochemistry and Biophysics</i> , <b>2012</b> , 527, 81-9	4.1	238
68	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1413-25	15.1	211
67	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , <b>2012</b> , 33, 2719-47	9.5	2638
66	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , <b>2012</b> , 95, 241-8	7	46
65	Clinical use of aspirin in ischemic heart disease: past, present and future. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5215-23	3.3	7
64	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 699-708	59.2	765
63	Stroke prevention in atrial fibrillation: current status and near-future directions. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 793-9	2.4	16
62	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. <i>Atherosclerosis</i> , <b>2011</b> , 214, 397-403	3.1	36
61	Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, 579-86	8	97
60	Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes. <i>Vascular Pharmacology</i> , <b>2011</b> , 54, 68-74	5.9	108
59	Cellular and molecular mechanisms of vascular injury in diabetes--part II: cellular mechanisms and therapeutic targets. <i>Vascular Pharmacology</i> , <b>2011</b> , 54, 75-9	5.9	41
58	n-3 fatty acids in cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2439-50	59.2	446
57	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , <b>2011</b> , 32, 2922-32	9.5	160
56	Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 440-9	12.3	51
55	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2011</b> , 32, 1854-64	9.5	273

54	Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 69, 303-6	3.8	5
53	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , <b>2010</b> , 31, 2133-40	9.5	26
52	Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1450-5		44
51	Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. <i>European Heart Journal</i> , <b>2010</b> , 31, 1557-64	9.5	44
50	Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 198-211	15.1	74
49	Pharmacological modulation of vascular inflammation in atherothrombosis. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1207, 23-31	6.5	17
48	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2010</b> , 31, 2369-429	9.5	3452
47	Opportunities and challenges in nutrigenetics/nutrigenomics and health. <i>Journal of Nutrigenetics and Nutrigenomics</i> , <b>2010</b> , 3, 137-43		1
46	Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. <i>Cardiovascular Therapeutics</i> , <b>2010</b> , 28, e13-9	3.3	74
45	Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 1723-9	9.4	126
44	Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. <i>Atherosclerosis</i> , <b>2009</b> , 206, 540-5	3.1	62
43	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , <b>2009</b> , 10, 595-604	1.9	13
42	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 345-350	7	31
41	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , <b>2009</b> , 10, 446-53	1.9	3
40	Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2008</b> , 1782, 511-6	6.9	25
39	Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. <i>Hypertension Research</i> , <b>2008</b> , 31, 2137-46	4.7	63
38	Receiver operating characteristic (ROC) curves and the definition of threshold levels to diagnose coronary artery disease on electrocardiographic stress testing. Part II: the use of ROC curves in the choice of electrocardiographic stress test markers of ischaemia. <i>Journal of Cardiovascular Medicine</i> , <b>2008</b> , 9, 22-31	1.9	9
37	n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. <i>Diabetes Care</i> , <b>2007</b> , 30, 1012-26	14.6	93

36	Vasculoprotective potential of olive oil components. <i>Molecular Nutrition and Food Research</i> , <b>2007</b> , 51, 1225-34	5.9	73
35	Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2007</b> , 293, H2344-54	5.2	94
34	Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. <i>European Heart Journal</i> , <b>2007</b> , 28, 484-91	9.5	26
33	Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. <i>Hypertension</i> , <b>2007</b> , 50, 325-32	8.5	216
32	Universal definition of myocardial infarction. <i>Circulation</i> , <b>2007</b> , 116, 2634-53	16.7	1953
31	Omega-3 fatty acids, atherogenesis, and endothelial activation. <i>Journal of Cardiovascular Medicine</i> , <b>2007</b> , 8 Suppl 1, S11-4	1.9	13
30	Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply. <i>European Heart Journal</i> , <b>2007</b> , 28, 2419-2420	9.5	
29	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , <b>2007</b> , 28, 880-913	9.5	94
28	Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 59-65	15.1	51
27	Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , <b>2006</b> , 83, 421S-426S	7	92
26	Recommendations for the management of patients after heart valve surgery. <i>European Heart Journal</i> , <b>2005</b> , 26, 2463-71	9.5	260
25	Distal embolization during primary angioplasty: histopathologic features and predictability. <i>American Heart Journal</i> , <b>2005</b> , 150, 102-8	4.9	80
24	At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2005</b> , 25, 1401-7	9.4	168
23	Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 13503-11	5.4	73
22	Nutrients and gene expression. <i>World Review of Nutrition and Dietetics</i> , <b>2004</b> , 93, 99-133	0.2	9
21	Effects of omega-3 fatty acids on cytokines and adhesion molecules. <i>Current Atherosclerosis Reports</i> , <b>2004</b> , 6, 485-91	6	47
20	From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 4-7	59.2	140
19	Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. <i>American Heart Journal</i> , <b>2004</b> , 148, e6	4.9	22



18	Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. <i>Cardiovascular Research</i> , <b>2004</b> , 63, 582-92	9.9	657
17	New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , <b>2004</b> , 5 Suppl 6, 19S-24S		1
16	Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 622-9	9.4	504
15	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. <i>American Heart Journal</i> , <b>2003</b> , 146, 420-30	4.9	57
14	Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , <b>2003</b> , 4, 228-31		
13	Quenching of Intracellular ROS Generation as a Mechanism for Oleate-Induced Reduction of Endothelial Activation and Early Atherogenesis. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 335-344	7	61
12	Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. <i>Circulation</i> , <b>2002</b> , 106, 2543-9	16.7	102
11	Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. <i>Circulation</i> , <b>2002</b> , 105, 816-22	16.7	454
10	Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 335-44	7	18
9	<sup>111</sup> In platelet scintigraphy for the noninvasive detection of carotid plaque thrombosis. <i>Stroke</i> , <b>2001</b> , 32, 719-27	6.7	23
8	n-3 fatty acids: antiatherosclerotic effects. <i>Lipids</i> , <b>2001</b> , 36 Suppl, S69-78	1.6	41
7	Endothelial dysfunctions: common denominators in vascular disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2000</b> , 3, 453-67	3.8	36
6	Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. <i>Circulation Research</i> , <b>2000</b> , 87, 19-25	15.7	159
5	Oleic acid inhibits endothelial activation : A direct vascular antiatherogenic mechanism of a nutritional component in the mediterranean diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 220-8	9.4	166
4	Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 2646-54	9.4	212
3	Control of endothelial leukocyte adhesion molecules by fatty acids. <i>Lipids</i> , <b>1996</b> , 31 Suppl, S57-63	1.6	108
2	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , <b>1985</b> , 55, 589-90	3	27
1	Antithrombotic Management in Patients with Prosthetic Valves246-271		3

